US Oncology Network

The Enhancing Oncology Model (EOM) attracted more than 2800 practitioners across 561 sites of care; a group of practices in the American Oncology Network enrolled under a single tax ID number.

In a statement, The US Oncology Network said the addition expands its reach into Kansas, continues pattern of strong growth in 2023.

While the final number of EOM practices will be fewer than the numbers in the OCM, the presence of Tennessee Oncology, Texas Oncology, and Northwest Medical Specialties will ensure participation of key leaders who succeeded in the OCM and have weighed in on what's needed in its replacement.

Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology, discusses how collaboration between oncologists and primary care physicians (PCPs) can improve patient satisfaction and outcomes.

The session, “Payment Reform: Lessons Learned from the Oncology Care Model (OCM) and Implications for the Enhancing Oncology Model (EOM)," comes less than a month before the EOM is set to begin.

An expert panel at the recent meeting of the Quality Cancer Care Alliance discussed the Enhancing Oncology Model (EOM), which is set to begin on July 1, 2023.

Oncologists express concerns about the replacement for the Oncology Care Model; the EOM is set to start July 1, 2023.

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.

Regional Cancer Care Associates (RCCA) has entered into a strategic relationship with The US Oncology Network, effective April 1, 2023.

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses recent findings from studies he participated in on targeted therapies for muscle-invasive bladder cancer.

Ben Jones, vice president of Government Relations and Public Policy at the US Oncology Network, discussed the Enhancing Oncology Model (EOM), and why it's such an important topic at this year's conference.

At Patient-Centered Oncology Care®, Debra Patt, MD, PhD, MBA, of Texas Oncology, discussed managed care considerations that arise from the groundbreaking DESTINY-Breast04 study presented earlier this year.

News from our Strategic Alliance Partners.

New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.

Evidence-Based Oncology™️ spoke with Lyons about the creation of this real-world data set and the pros and cons of different treatments for MDS.

An analysis presented during the 64th American Society of Hematology Annual Meeting and Exposition showed that patients with multiple myeloma were able to experience improved responses to the proteasome inhibitor ixazomib after switching from bortezomib.

Patient quality of life can be improved through shared knowledge between doctors and patients in cancer care using the Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Tool calculator, which Rocky Mountain Cancer Centers piloted, explained Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

New immunotherapies are changing the shape of oncology care, but there is also a need for a system that provides these high-quality therapies to the patients most likely to benefit from them. This might mean doing an assessment and a deeper dive into patient functional status, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

A tool to measure chemotherapy toxicity from the Cancer and Aging Research Group can help determine emergency department visits or hospitalization risk, especially for elderly patients, says Alonso V. Pacheco, MD, medical director and medical oncologist/hematologist, Rocky Mountain Cancer Centers.

Constructive advice on improving the Enhancing Oncology Model (EOM) from our expert panel.

The Enhancing Oncology Model allows pooling of groups of practices for quality measurement, which was not permitted under the OCM.

Asking for help to prepare for the Enhancing Oncology Model (EOM) and 2-sided risk is advised, say panelists experienced with the Oncology Care Model (OCM).